Skip to main content

Published locations for KEYNOTE-054: Adjuvant pembrolizumab beat placebo in high-risk resected melanoma

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. KEYNOTE-054: Adjuvant pembrolizumab beat placebo in high-risk resected melanoma

User login

  • Reset your password
  • /content/keynote-054-adjuvant-pembrolizumab-beat-placebo-high-risk-resected-melanoma
  • /edermatologynews/article/163497/immuno-oncology/keynote-054-adjuvant-pembrolizumab-beat-placebo-high
  • /oncologypractice/article/163497/immuno-oncology/keynote-054-adjuvant-pembrolizumab-beat-placebo-high
  • /hematology-oncology/article/163497/immuno-oncology/keynote-054-adjuvant-pembrolizumab-beat-placebo
  • /dermatology/article/163497/immuno-oncology/keynote-054-adjuvant-pembrolizumab-beat-placebo-high-risk